Search
Plitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatm...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesP-113D
go.drugbank.com/drugs/DB04987ExperimentalP-113D is a novel 12 amino-acid antimicrobial peptide drug derived from histatins, which are compounds found naturally in human saliva.
Methsuximide
go.drugbank.com/drugs/DB05246ApprovedMesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsInterferon alfa
go.drugbank.com/drugs/DB05258ApprovedInvestigationalWithdrawnNatural interferon alpha or Multiferon is obtained from the leukocyte fraction of human blood following induction with Sendai virus. Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromato...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsAlbinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalAlbumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified i...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsMavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalMavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficienc...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLevoketoconazole
go.drugbank.com/drugs/DB05667ApprovedCushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying changes in body composition, neurops...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strateg...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates3,4-Methylenedioxy-N-isopropylamphetamine
go.drugbank.com/drugs/DB06112ExperimentalMDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").
Synonyms: MDI-PSpiramycin
go.drugbank.com/drugs/DB06145ApprovedInvestigationalWithdrawnSpiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii an...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Enzyme Inhibitors